Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Hemophilia B: Gene Therapy Shows Promise
TOPLINE: Fidanacogene elaparvovec gene therapy reduced the annualized bleeding rate by 71% in patients with hemophilia B. Factor IX activity levels were sustained at 26.9% at 15 months post-treatment. METHODOLOGY: A phase 3 open-label study was conducted involving 45 men…
English